Scope of the Study
The glial cell-derived neurotrophic factor is defined as the small protein which potently promotes the survival of numerous types of neurons. In addition, it is mostly found to be effective in preventing the apoptosis of motor neurons which is induced by axotomy. Brain ischemia, retinal degeneration, Parkinson's disease, amyotrophic lateral sclerosis are some of the major application of glial cell line-derived neurotrophic factor market. According to an article published by the Parkinson Association of the Carolinas, more than 7 to 10 million people are suffering from Parkinson's disease. Hence, growth in the aging population and the associated increase in the prevalence of Parkinson's disease and government funding for research are likely to be a prime driver for the global Parkinson's disease treatment market
The market study is being classified by Type (GSK-812, LAUR-301, TW-002, AMT-090 and Other), by Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinsonís Disease, Retinal Degeneration and Others) and major geographies with country level break-up.
GlaxoSmithKline Plc (United Kingdom), Treeway BV (Netherlands) and UniQure NV (Netherlands) are some of the key players profiled in the study.
Research Analyst at AMA predicts that Netherlands Players will contribute to the maximum growth of Global Glial Cell Line Derived Neurotrophic Factor market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Glial Cell Line Derived Neurotrophic Factor market by Type, Application and Region.
On the basis of geography, the market of Glial Cell Line Derived Neurotrophic Factor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
- Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson ís Disease
- Government Funding for Research and Rising Healthcare Awareness Globally
- Advancements in Technology have linked the Importance of GDNF in the Treatment of Parkinsonís disease,
- Issue related to Availability of Alternative Treatments
- Rising Demand from Emerging Economics such as China, India, among others
- Government Initiatives to Expand the Glial Cell Line-Derived Neurotrophic Factor Market
- The problem regarding Strong Drug Pipeline
According to an article published by Parkinson Association of the Carolinas, every year more than 60,000 people in the United States are diagnosed with Parkinson's disease. Therefore, this will, in turn, propel the growth of glial cell line-derived neurotrophic Factor market.
Key Target AudienceGlial Cell-Derived Neurotrophic Factor Manufacturers, Regulatory bodies, Intermediary Suppliers and End Users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase